| Document |
Document Title |
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/134641A1 |
An aromatic heterocyclic compound, a pharmaceutical composition and use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt of any on...
|
|
WO/2022/136365A1 |
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is β-D-galactopyranose. A1 is (II) wherein the asterix * indicates the nitrogen atom of the triazole ring that is covalently attached...
|
|
WO/2022/138888A1 |
The purpose of the present invention is to provide a compound having a tetrahydroquinoline skeleton, said compound having ferroptosis inhibitory action and exhibiting a treatment effect or a prevention effect for a disease, disorder, or ...
|
|
WO/2022/135580A1 |
A crystal form of a pyridopyrrole compound, and a preparation method therefor and the use thereof.
|
|
WO/2022/140290A1 |
Provided herein are compounds of formula (A): or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, Ry, and Rz are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...
|
|
WO/2022/133480A1 |
The present invention provides AHR agonists, composites thereof, and methods of using the same.
|
|
WO/2022/130270A1 |
Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use...
|
|
WO/2022/133078A1 |
Disclosed herein are compounds and compositions effective for modulation of Tie-2 and HPTP-beta. The compounds can provide effective therapy for vascular disease, including those associated with inflammation and leakage, pathologic neova...
|
|
WO/2022/129925A1 |
The present disclosure relates to a novel class of bifunctional molecules that are useful in a targeted or selective degradation of a protein.
|
|
WO/2022/127917A1 |
The present invention provides a benzoheterocycle substituted tetrahydroisoquinoline compound, and in particular, relates to a compound shown in formula (I) and a pharmaceutically acceptable salt thereof, and the compound for the treatme...
|
|
WO/2022/129365A1 |
The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing thes...
|
|
WO/2022/132609A1 |
This disclosure relates to compounds having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such compounds and intermediates used in such processes, compositions containing such compo...
|
|
WO/2022/131741A1 |
The present invention relates to an isoxazolidine derivative compound and the use thereof. The isoxazolidine derivative compound of the present invention exhibits excellent inhibitory activity against CDK2, CDK4, CDK6 and/or HPK1, and th...
|
|
WO/2022/130406A1 |
The present invention relates to an inhalation composition comprising nitazoxanide or its derivatives to a patient (e.g., a human). The present invention further relates to method of treating Coronavirus disease by administering nitazoxa...
|
|
WO/2022/123039A1 |
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain aldehyde dehydrogenase inhibitor compounds (also referred to herein as "ALDHI compounds"), that, ...
|
|
WO/2022/125636A1 |
Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compo...
|
|
WO/2022/121805A1 |
The present invention provides a fused ring compound as a sodium channel blocker and a use thereof. The fused ring compound has inhibitory activity on a sodium ion channel Nav1.8, and can be used as a drug for extensive pain treatment.
|
|
WO/2022/120442A1 |
This invention provides novel codrugs having covalently bound promoieties displaying angiotensin II type 1 receptor (AT1) antagonism and neprilysin (NEP) inhibition and processes of manufacturing thereof. The invention also includes phar...
|
|
WO/2022/122014A1 |
Provided are a new crystal form of Lanifibranor (referred to as "compound I") and a preparation method therefor, a pharmaceutical composition containing the crystal form, and a use of the crystal form in preparation of a pan-PPAR agonist...
|
|
WO/2022/118910A1 |
[Problem] The purpose of the present invention is to provide a compound that has a high refractive index with respect to the wavelength range of 450-750 nm in a capping layer, in order to improve the light extraction efficiency of an org...
|
|
WO/2022/120118A1 |
Novel small molecule proteolysis-targeting chimeras (PROTACs) are provided, along with methods for their use as RIPK1 kinase degraders. The small molecule PROTACs described herein are useful in treating and/or preventing RIPK1 kinase-rel...
|
|
WO/2022/087422A9 |
The present disclosure relates to compounds of Formula (I'): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are use...
|
|
WO/2022/117016A1 |
The present invention relates to a hydroxamate compound represented by formula (I), a preparation method therefor, and an application thereof. The present invention also relates to a pharmaceutical composition comprising the compound as ...
|
|
WO/2022/118210A1 |
Disclosed herein are certain thiadiazolyl derivatives of Formula (I), (II), (III), or (IV): (I), (II), (III), (IV) that inhibit DNA Polymerase Theta (Polθ) activity, in particular inhibit Polθ activity by inhibiting ATP dependent helic...
|
|
WO/2022/117064A1 |
Provided herein are heteroaryl-acetylene compounds, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of...
|
|
WO/2022/120355A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2022/119174A1 |
Provided is a dibenzo 5-membered cyclic compound that contributes to substantial improvements in the light efficiency and viewing angle of an organic electroluminescence device. The organic electroluminescence device according to the pre...
|
|
WO/2022/112207A1 |
The present invention provides novel compounds having the general formula wherein A1 to A4, X1, Rx, Ry, Cy, L and R1 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/112140A1 |
The present invention provides novel compounds having the general formula (I) wherein Al to A4, Li, L2, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds for the treatment of HBV i...
|
|
WO/2022/115620A1 |
The present invention refers to 4-Fluoro-(4-(4-Benzyl)piperidin-l-yl) (2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds of formula (I) as CYP46A1 inhibitors for the treatment of neurodegenerative disorders, epil...
|
|
WO/2022/112352A1 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2022/111708A1 |
The present invention relates to a deuterated 3-oxo-2,3-dihydropyridazine-4-carboxamide inhibitor, a preparation method therefor, and an application thereof. Specifically, the compound of the present invention has the structure shown in ...
|
|
WO/2022/112490A1 |
The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositio...
|
|
WO/2022/112188A1 |
The present invention provides novel compounds having the general formula: (I) wherein R1 to R3 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/111605A1 |
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...
|
|
WO/2022/112919A1 |
This application includes a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein the variables R1a, R1b, R2, R3, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I ...
|
|
WO/2022/112493A1 |
The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions c...
|
|
WO/2022/113972A1 |
The present invention addresses the problem of providing a thiabendazole-containing composition for pest control which is reduced in color tone change due to light or heat, is less apt to decompose at high temperatures, and is inhibited ...
|
|
WO/2022/115879A1 |
The present disclosure relates to compounds and pharmaceutical compositions thereof, and methods of using the compounds and compositions in therapy, such as methods of treating cancer.
|
|
WO/2022/112139A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R3 are as described herein, or a pharmaceutically acceptable salt thereof, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/112491A1 |
The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are (aza)quinoline 4-amines derivatives, methods of preparing such compounds, pharmaceutical co...
|
|
WO/2022/105782A1 |
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a benzisothiazole compound, and a preparation method therefor and a pharmaceutical composition and use thereof. In particular, the present invention re...
|
|
WO/2022/107724A1 |
The present invention provides: a novel azetidinone derivative having excellent herbicidal activity, or a salt thereof; an herbicide containing the same as an active ingredient; and a production intermediate. Provided are: an azetidinone...
|
|
WO/2022/109307A1 |
The disclosure herein provides combination therapies for the treatment of KRAS mutant cancers. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula I or a pharmaceutically acceptab...
|
|
WO/2022/105746A1 |
Provided are certain BTK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2022/108377A1 |
The present invention relates to a novel compound having inhibitory activity against O-GlcNAcase and a use thereof.
|
|
WO/2022/106375A1 |
The present invention provides novel compounds having the general formula (I) wherein A, L, and B are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2022/106588A1 |
The present invention provides novel compounds having the general formula: wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.
|
